Selected data models

You must log in to select data models for download or further analysis.

10 Search results.
Relevance Rating New first Old first

Visit 1 GIMEMA CML0408 NCT00769327 - Visit 1

- 9/20/21 - 1 form, 15 itemgroups, 150 items, 2 languages
Itemgroups: Previous chemotherapy, Comorbidities, Symptoms, Physical Examination, Complete Blood Count, Biochemistry, Serum Proteins, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, FISH (from bone marrow blood), Molecular Biology (peripheral blood), FISH (peripheral blood)
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 1 Form

ATC L - Antineoplastic and immunomodulating agents

- 9/20/21 - 1 form, 1 itemgroup, 1 item, 2 languages
Itemgroup: Antineoplastic and immunomodulating agents
modified from epSOS value set 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 http://www.epsos.eu http://www.whocc.no/atc_ddd_index/ WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2015. Oslo, Norway 2014 Copyright ATC index: WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway Copying and distribution for commercial purposes is not allowed. German ATC-Index: Datenquelle des amtlichen ATC-Index mit DDD-Angaben: GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO), AOK Bundesverband GbR Stand September 2015. Nur nicht-kommerzielle Nutzung zulässig

Palliative and Hospice Care Tumor-specific Therapies in Palliative Care

- 9/17/21 - 1 form, 13 itemgroups, 43 items, 2 languages
Itemgroups: Date, TT1. Type of therapy, TT2. Number of previous treatments, TT3. Indications, TT4. Agents/Regime/Modus, TT5. Medical indication assessed by, TT6. Palliative prognostic index PPI in pre-treatment/ starting the new indicated tumor treatment, TT7. Was proceding/start of tumor therapy based on consensus in the palliative team?, TT8. What was the subjective success of the tumor therapy?, TT9. Was the tumor therapy determined early?, TT10. If yes, what were the reasons for the discontinuation of tumor therapy?, TT11. Was discontinuation of tumor therapy based on consensus in the palliative team?, TT12. Who completes this questionnaire?
https://www.hope-clara.de/ The HOPE Hospice and Palliative Care Recording standard documentation is used for documentation of palliative care and as an instrument for quality assurance in pallatiave wards, hospices and oncological wards as well as in ambulatory services and palliative teams. This questionnaire is designed to record tumor-specific therapies.

Eligibility Squamous Cell Carcinoma of the Head and Neck NCT02454179

- 6/30/21 - 1 form, 2 itemgroups, 8 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02454179

Eligibility Primary Cutaneous Anaplastic Large Cell Lymphoma, NCT01578499

- 6/22/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01578499

Eligibility Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma NCT01514344

- 6/20/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01514344

Eligibility Thymoma and Thymic Carcinoma NCT02049047

- 6/11/21 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02049047

Eligibility Lymphoma, Follicular NCT01902862

- 4/7/17 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01902862

Eligibility Lymphoma NCT00740415

- 4/7/17 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Criteria
Rituximab, Bortezomib, Doxorubicin, Dexamethasone, and Chlorambucil Patients With Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00740415

Manual for tumor documentation in MEDICO Appendix 1 - Manual for tumor documentation in MEDICO- Appendix 1: Substances in systemic treatment

- 2/1/17 - 1 form, 10 itemgroups, 33 items, 1 language
Itemgroups: cytostatics, Hormones, Cytokines, Monoclonal antibodies, Signaltransduction-Inhibitors (STI), Other "new substances", Antiemetics, Supportives, Bisphosphonates, Vaccines
"Zur Dokumentation der Tumorerkrankungen wurde in Medico eine dem ADT/ GEKID konforme Tumordokumentation eingerichtet. Sukzessive wurde sie mit zusätzlichen Merkmalen ergänzt, damit alle notwendigen Informationen, die auch zur vollständigen Dokumentation der Tumorboardbeschlüsse und zur Bedienung diverser Anfragen erforderlich sind, in Medico abrufbar sind." Dieses Handbuch bezieht sich auf die Tumordokumentation im "Basisbogen" der Medico-Tumordokumentation und auf die Dokumentation solider Tumore. Spezifische Dokumentationsmerkmale für systemische Erkrankungen und multiple Hauttumore werden folgen. Für die Anlage des Basisbogens in Medico und Anmeldung zum Tumorboard sowie für die Dokumentation des Tumorboards inklusive des zugehörigen Beschlusses wurde jeweils eine eigene Anleitung erstellt. Diese stehen allen Mitarbeiterinnen und Mitarbeitern im QM-Handbuch des UK Essen über das Dokumentenmanagementsystem roXtra zur Verfügung. https://roxtra.uk-es-sen.de/Roxtra/preview/pdf/Anlegen+des+Basisbogens+und+Anmeldung+zur+Tumorkonferenz.pdf?Type=PDF&FileID=33846 https://roxtra.uk-essen.de/Roxtra/preview/pdf/Dokumentation+der+Tumorkonferenz.pdf?Type=PDF&FileID=33851

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial